Mind Medicine (MindMed) Inc. (MNMD)

Market Cap	466.53M
Revenue (ttm)	n/a
Net Income (ttm)	-108.68M
Shares Out	75.37M
EPS (ttm)	-1.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,073,927
Open	6.38
Previous Close	6.43
Day's Range	6.10 - 6.47
52-Week Range	5.03 - 12.22
Beta	2.40
Analysts	Strong Buy
Price Target	25.75 (+315.99%)
Earnings Date	Mar 6, 2025

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: MNMD
• Website: https://www.mindmed.co

Analyst Forecast

According to 9 analysts, the average rating for MNMD stock is "Strong Buy." The 12-month stock price forecast is $25.75, which is an increase of 315.99% from the latest price.

Price Target

$25.75

(315.99% upside)

Analyst Consensus: Strong Buy